CooperVision reveals virtual exhibit booth

Article

Products and services to be showcased online

More and more in-person events are revealing online alternatives, as COVID-19 expands its reach. So far this year, 3 major optometric conferences— Vision Expo East, Vision Expo West and American Optometric Association’s Optometry’s Meeting— have announced cancellations and there is speculation that more will follow suit.

In response to industry meetings moving to virtual venues, CooperVision has rolled out a virtual exhibit booth to offer eyecare professionals a chance to collaborate from the safety of their homes. Attendees can expect an experience similar to that of an in-person conference, with education, industry discussion and exhibits at the forefront, according to the company.

Related: Vision Expo West 2020 cancelled due to COVID-19

The booth is available now and will be continuously open to virtual attendees at Vision Expo West in September and the American Academy of Optometry meeting, if it moves to a virtual setting, according to the company.

The virtual booth will feature a 3D rendering of the live CooperVision exhibit and multimedia materials showcasing the latest news and product information. Atendees will experience the following:

• Learn how CooperVision is supporting eyecare professionals and their practices during the pandemic.

• Explore CooperVision’s newest contact lens—Biofinity toric multifocal

• Dive into information on the Brilliant FuturesMyopia Management Program

• Learn more about the recent expansion of prescription options for clariti 1 day toric

• Get to know CooperVision’s 2020 Best Practices honorees

• Discover the breadth of CooperVision’s commitment to sustainability

Related: CooperVision awards Future Contact Lens Leader scholarship recipients

“Conferences are always invaluable opportunities for us to connect with practitioners from around the country, share with them the most recent developments in product and partnership, and hear from them about what they want and need for their practices,” says Michele Andrews, OD, senior director of professional and academic affairs at CooperVision, in a statement.

“We’re disappointed not to have that face-to-face interaction right now, but we must adapt to continue our collaboration, even when we’re separated by distance. The virtual exhibit booth is part of that effort, offering our customers a convenient way to explore all of our latest news, all in one place.”

CooperVision plans to update the virtual exhibit booth with new information and materials as developments arise.

Related: Ptosis therapy gets first-in-category FDA nod

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.